Monte Rosa Therapeutics, Inc. (GLUE) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 4.7M | 1.06M | 0 | 0 | 0 |
| Revenue Growth % | -95.04% | -95.41% | 38.54% | 394.01% | 7882.05% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 2.03M | 0 | 0 | 0 | 0 | 0 | 0 | 2.06M | 1.9M | 0 | 0 | 0 |
| COGS % of Revenue | 48.19% | - | - | - | - | - | - | 43.88% | 178.29% | - | - | - |
| Gross Profit | 2.18M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 2.63M | -833K | 0 | 0 | 0 |
| Gross Margin % | 51.81% | 100% | 100% | 100% | 100% | 100% | 100% | 56.12% | -78.29% | - | - | - |
| Gross Profit Growth % | -97.43% | -95.41% | 38.54% | 780.23% | 10295.56% | - | - | - | - | - | - | - |
| Operating Expenses | 52.22M | 52.5M | 45.74M | 38.75M | 40.89M | 47.64M | 35.74M | 35.28M | 34.11M | 34.86M | 36.97M | 37.22M |
| OpEx % of Revenue | 1240.26% | 1887.67% | 358.26% | 167.06% | 48.15% | 78.56% | 387.84% | 751.37% | 3206.2% | - | - | - |
| Selling, General & Admin | 10.18M | 10.52M | 9.06M | 8.1M | 8.7M | 8.78M | 8.13M | 9.28M | 8.98M | 7.73M | 8.66M | 8.14M |
| SG&A % of Revenue | 241.69% | 378.17% | 71% | 34.9% | 10.25% | 14.47% | 88.18% | 197.7% | 844.45% | - | - | - |
| Research & Development | 44.07M | 41.98M | 36.68M | 30.65M | 32.19M | 38.87M | 27.62M | 26M | 25.13M | 27.14M | 28.31M | 29.08M |
| R&D % of Revenue | 1046.77% | 1509.49% | 287.26% | 132.16% | 37.9% | 64.09% | 299.65% | 553.67% | 2361.75% | - | - | - |
| Other Operating Expenses | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 0 |
| Operating Income | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M | 13M | -26.53M | -32.64M | -34.95M | -34.86M | -36.97M | -37.22M |
| Operating Margin % | -1188.46% | -1787.67% | -258.26% | -67.06% | 51.85% | 21.44% | -287.84% | -695.25% | -3284.49% | - | - | - |
| Operating Income Growth % | -213.62% | -482.31% | -24.31% | 52.35% | 226.01% | 137.3% | 28.24% | 12.3% | -2.01% | -7.31% | -30.34% | -36.69% |
| EBITDA | -48.01M | -47.63M | -30.88M | -13.43M | 46.08M | 15.06M | -24.42M | -30.58M | -33.05M | -33.02M | -35.13M | -35.83M |
| EBITDA Margin % | -1140.26% | -1712.59% | -241.85% | -57.9% | 54.26% | 24.84% | -265.02% | -651.37% | -3106.2% | - | - | - |
| EBITDA Growth % | -204.17% | -416.14% | -26.43% | 56.09% | 239.44% | 145.63% | 30.48% | 14.65% | 0.18% | -5.09% | -28.56% | -36.02% |
| D&A (Non-Cash Add-back) | 2.03M | 2.09M | 2.1M | 2.13M | 2.05M | 2.06M | 2.1M | 2.06M | 1.9M | 1.85M | 1.83M | 1.39M |
| EBIT | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M | 13M | -26.53M | -32.64M | -34.95M | -34.86M | -36.97M | -37.22M |
| Net Interest Income | 5.59M | 3.69M | 2.75M | 3.07M | 3.44M | 2.6M | 2.89M | 2.64M | 2.44M | 2.37M | 2.23M | 2.3M |
| Interest Income | 5.59M | 3.69M | 2.75M | 3.07M | 3.44M | 2.6M | 2.89M | 2.64M | 2.44M | 2.37M | 2.23M | 2.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 5.58M | 3.64M | 2.72M | 4.46M | 3.67M | 2.6M | 2.74M | 2.58M | 3.06M | 1.59M | 2.25M | 2.23M |
| Pretax Income | -44.45M | -46.08M | -30.26M | -11.1M | 47.71M | 15.6M | -23.79M | -30.06M | -31.89M | -33.27M | -34.71M | -34.99M |
| Pretax Margin % | -1055.84% | -1656.81% | -236.98% | -47.84% | 56.17% | 25.72% | -258.12% | -640.21% | -2996.71% | - | - | - |
| Income Tax | 52K | 59K | -3.18M | 1.2M | 822K | 2.16M | 71K | 252K | 83K | -22K | 170K | 190K |
| Effective Tax Rate % | -0.12% | -0.13% | 10.5% | -10.81% | 1.72% | 13.87% | -0.3% | -0.84% | -0.26% | 0.07% | -0.49% | -0.54% |
| Net Income | -44.5M | -46.13M | -27.08M | -12.29M | 46.88M | 13.44M | -23.86M | -30.31M | -31.97M | -33.25M | -34.88M | -35.18M |
| Net Margin % | -1057.08% | -1658.94% | -212.1% | -53.01% | 55.2% | 22.16% | -258.89% | -645.58% | -3004.51% | - | - | - |
| Net Income Growth % | -194.92% | -443.34% | -13.5% | 59.44% | 246.66% | 140.41% | 31.6% | 13.84% | 0.22% | -8.02% | -27.7% | -32.9% |
| Net Income (Continuing) | -44.5M | -46.13M | -27.08M | -12.29M | 46.88M | 13.44M | -23.86M | -30.31M | -31.97M | -33.25M | -34.88M | -35.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.68 | -0.70 | -0.33 | -0.15 | 0.57 | 0.22 | -0.29 | -0.43 | -0.53 | -0.58 | -0.70 | -0.71 |
| EPS Growth % | -219.3% | -418.18% | -13.79% | 65.12% | 207.55% | 137.93% | 58.57% | 39.44% | 11.67% | 1.69% | -25% | -29.09% |
| EPS (Basic) | -0.68 | -0.70 | -0.33 | -0.15 | 0.57 | 0.22 | -0.29 | -0.43 | -0.53 | -0.58 | -0.70 | -0.71 |
| Diluted Shares Outstanding | 65.54M | 65.54M | 82.4M | 82.19M | 82.96M | 61.44M | 82.01M | 71.23M | 60.16M | 56.93M | 49.81M | 49.43M |
| Basic Shares Outstanding | 65.54M | 65.54M | 82.4M | 82.19M | 82.15M | 61.44M | 82.01M | 71.23M | 60.16M | 56.93M | 49.81M | 49.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |